WallStSmart

Novartis AG ADR (NVS)vsTenon Medical Inc (TNON)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 1434433% more annual revenue ($56.58B vs $3.94M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96

TNON

Avoid

30

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued
TNONUndervalued (+52.5%)

Margin of Safety

+52.5%

Fair Value

$1.50

Current Price

$0.76

$0.74 discount

UndervaluedFair: $1.50Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

TNON1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
92.3%10/10

Revenue surging 92.3% year-over-year

Areas to Watch

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

TNON4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.60M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-228.1%2/10

ROE of -228.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : TNON

The strongest argument for TNON centers on Revenue Growth. Revenue growth of 92.3% demonstrates continued momentum.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Bear Case : TNON

The primary concerns for TNON are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

NVS profiles as a declining stock while TNON is a hypergrowth play — different risk/reward profiles.

TNON carries more volatility with a beta of 1.25 — expect wider price swings.

TNON is growing revenue faster at 92.3% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 30/100), backed by strong 23.9% margins. TNON offers better value entry with a 52.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Tenon Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and outcomes. The company is headquartered in Los Gatos, California.

Want to dig deeper into these stocks?